MYCOPHENOLATE MOFETIL HYDROCHLORIDE vs TACROLIMUS

Compare MYCOPHENOLATE MOFETIL HYDROCHLORIDE (Mycophenolate Mofetil) and TACROLIMUS (Tacrolimus) — clinical data, side effects, and patient experiences.

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

Mycophenolate Mofetil · Immunosuppressant

How it works

12.1 Mechanism of Action Mycophenolate mofetil (MMF) is absorbed following oral administration and hydrolyzed to mycophenolic acid (MPA), the active metabolite. MPA is a selective ...

Approved for

1 INDICATIONS AND USAGE Mycophenolate Mofetil [mycophenolate mofetil (MMF)] is indicated for the prophylaxis of organ rejection

in adult and pediatric recipients 3 months of age and older of allogeneic kidney [see Clinical Studies (14.1) ]

heart [see Clinical Studies (14.2) ] or liver transplants [see Clinical Studies (14.3) ]

heart or liver transplants

IntravenousTablet

TACROLIMUS

Tacrolimus · Immunosuppressant

How it works

12.1 Mechanism of Action Tacrolimus binds to an intracellular protein, FKBP-12. A complex of tacrolimus-FKBP-12, calcium, calmodulin, and calcineurin (a ubiquitous mammalian intrac...

Approved for

1 INDICATIONS AND USAGE Tacrolimus capsules are calcineurin-inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in adult patients receiving allogeneic liver

kidney or heart transplants and pediatric patients receiving allogeneic liver transplants in combination with other immunosuppressants. ( 1.1 ) 1.1 Prophylaxis of Organ Rejection in Kidney

Liver or Heart Transplant Tacrolimus capsules are indicated for the prophylaxis of organ rejection

in adult patients receiving allogeneic kidney transplant [ see Clinical Studies (14.1) ]

OralTablet

Quick Comparison

MYCOPHENOLATE MOFETIL HYDROCHLORIDETACROLIMUS

Drug Class

Immunosuppressant

Route

Intravenous

Oral

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

Drug Not Working

>10%

Diarrhea

1-10%

Fever

1-10%

Nausea

0.1-1%

Fatigue

0.1-1%

Condition Worsened

0.1-1%

Shortness of Breath

0.1-1%

Vomiting

0.1-1%

TACROLIMUS

Drug Not Working

>10%

Diarrhea

1-10%

Fever

1-10%

FDA Warnings

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

5 WARNINGS AND PRECAUTIONS Blood Dyscrasias (Neutropenia, Red Blood Cell Aplasia): Monitor with blood tests; consider treatment interruption or dose reduction
1 Embryofetal Toxicity Use of MMF during pregnancy is associated with an increased risk of first trimester pregnancy loss and an increased risk of congenital malformations, especially external ear and other facial abnormalities including cleft lip and palate, and anomalies of the distal limbs, heart, esophagus, kidney and nervous system
Females of reproductive potential must be made aware of these risks and must be counseled regarding pregnancy prevention and planning
2 Lymphoma and Other Malignancies Patients receiving immunosuppressants, including Mycophenolate Mofetil, are at increased risk of developing lymphomas and other malignancies, particularly of the skin [see Adverse Reactions (6

TACROLIMUS

5 WARNINGS AND PRECAUTIONS Not Interchangeable with Extended Release Tacrolimus Products-Medication Errors : Instruct patients or caregivers to recognize the appearance of tacrolimus capsules
5 ) Neurotoxicity: Including risk of Posterior Reversible Encephalopathy Syndrome (PRES), monitor for neurologic abnormalities; reduce or discontinue tacrolimus
9 ) Not recommended for use with sirolimus: Not recommended in liver and heart transplant due to increased risk of serious adverse reactions
1 Lymphoma and Other Malignancies Patients receiving immunosuppressants, including tacrolimus, are at increased risk of developing lymphomas and other malignancies, particularly of the skin

Clinical Trial Data

No head-to-head clinical studies found for MYCOPHENOLATE MOFETIL HYDROCHLORIDE vs TACROLIMUS.

MYCOPHENOLATE MOFETIL HYDROCHLORIDE vs TACROLIMUS: What You Should Know

Key Differences

Both MYCOPHENOLATE MOFETIL HYDROCHLORIDE and TACROLIMUS belong to the Immunosuppressant class. While they share a similar mechanism of action, differences in pharmacokinetics, dosing, and side effect profiles may make one more suitable than the other for individual patients. MYCOPHENOLATE MOFETIL HYDROCHLORIDE is administered via Intravenous, whereas TACROLIMUS uses Oral. Route of administration can affect onset of action and patient adherence.

Safety Considerations

MYCOPHENOLATE MOFETIL HYDROCHLORIDE carries 4 FDA warnings. TACROLIMUS carries 4 FDA warnings. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.

Related Comparisons

EVEROLIMUS vs TACROLIMUS→EVEROLIMUS vs MYCOPHENOLATE MOFETIL HYDROCHLORIDE→SIROLIMUS vs TACROLIMUS→MYCOPHENOLATE MOFETIL HYDROCHLORIDE vs SIROLIMUS→CYCLOSPORINE OPHTHALMIC SOLUTION vs TACROLIMUS→CYCLOSPORINE OPHTHALMIC SOLUTION vs MYCOPHENOLATE MOFETIL HYDROCHLORIDE→

Loading comparison data...

MYCOPHENOLATE MOFETIL HYDROCHLORIDE vs TACROLIMUS

Compare MYCOPHENOLATE MOFETIL HYDROCHLORIDE (Mycophenolate Mofetil) and TACROLIMUS (Tacrolimus) — clinical data, side effects, and patient experiences.

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

Mycophenolate Mofetil · Immunosuppressant

How it works

12.1 Mechanism of Action Mycophenolate mofetil (MMF) is absorbed following oral administration and hydrolyzed to mycophenolic acid (MPA), the active metabolite. MPA is a selective ...

Approved for

1 INDICATIONS AND USAGE Mycophenolate Mofetil [mycophenolate mofetil (MMF)] is indicated for the prophylaxis of organ rejection

in adult and pediatric recipients 3 months of age and older of allogeneic kidney [see Clinical Studies (14.1) ]

heart [see Clinical Studies (14.2) ] or liver transplants [see Clinical Studies (14.3) ]

heart or liver transplants

IntravenousTablet

TACROLIMUS

Tacrolimus · Immunosuppressant

How it works

12.1 Mechanism of Action Tacrolimus binds to an intracellular protein, FKBP-12. A complex of tacrolimus-FKBP-12, calcium, calmodulin, and calcineurin (a ubiquitous mammalian intrac...

Approved for

1 INDICATIONS AND USAGE Tacrolimus capsules are calcineurin-inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in adult patients receiving allogeneic liver

kidney or heart transplants and pediatric patients receiving allogeneic liver transplants in combination with other immunosuppressants. ( 1.1 ) 1.1 Prophylaxis of Organ Rejection in Kidney

Liver or Heart Transplant Tacrolimus capsules are indicated for the prophylaxis of organ rejection

in adult patients receiving allogeneic kidney transplant [ see Clinical Studies (14.1) ]

OralTablet

Quick Comparison

MYCOPHENOLATE MOFETIL HYDROCHLORIDETACROLIMUS

Drug Class

Immunosuppressant

Route

Intravenous

Oral

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

Drug Not Working

>10%

Diarrhea

1-10%

Fever

1-10%

Nausea

0.1-1%

Fatigue

0.1-1%

Condition Worsened

0.1-1%

Shortness of Breath

0.1-1%

Vomiting

0.1-1%

TACROLIMUS

Drug Not Working

>10%

Diarrhea

1-10%

Fever

1-10%

FDA Warnings

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

5 WARNINGS AND PRECAUTIONS Blood Dyscrasias (Neutropenia, Red Blood Cell Aplasia): Monitor with blood tests; consider treatment interruption or dose reduction
1 Embryofetal Toxicity Use of MMF during pregnancy is associated with an increased risk of first trimester pregnancy loss and an increased risk of congenital malformations, especially external ear and other facial abnormalities including cleft lip and palate, and anomalies of the distal limbs, heart, esophagus, kidney and nervous system
Females of reproductive potential must be made aware of these risks and must be counseled regarding pregnancy prevention and planning
2 Lymphoma and Other Malignancies Patients receiving immunosuppressants, including Mycophenolate Mofetil, are at increased risk of developing lymphomas and other malignancies, particularly of the skin [see Adverse Reactions (6

TACROLIMUS

5 WARNINGS AND PRECAUTIONS Not Interchangeable with Extended Release Tacrolimus Products-Medication Errors : Instruct patients or caregivers to recognize the appearance of tacrolimus capsules
5 ) Neurotoxicity: Including risk of Posterior Reversible Encephalopathy Syndrome (PRES), monitor for neurologic abnormalities; reduce or discontinue tacrolimus
9 ) Not recommended for use with sirolimus: Not recommended in liver and heart transplant due to increased risk of serious adverse reactions
1 Lymphoma and Other Malignancies Patients receiving immunosuppressants, including tacrolimus, are at increased risk of developing lymphomas and other malignancies, particularly of the skin

Clinical Trial Data

No head-to-head clinical studies found for MYCOPHENOLATE MOFETIL HYDROCHLORIDE vs TACROLIMUS.

MYCOPHENOLATE MOFETIL HYDROCHLORIDE vs TACROLIMUS: What You Should Know

Key Differences

Safety Considerations

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.